Semler Scientific Inc Stock Price, News & Analysis

On April 3, 2023, Semler Scientific (SMLR) discussed the recent CMS 2024 Medicare Advantage and Part D Final Rate Announcement, specifically its decision to remove peripheral artery disease (PAD) without complications from the risk adjustment model. Despite this, CEO Wayne T. Pan expressed confidence in the importance of screening at-risk Medicare patients using the QuantaFlo® product. A three-year phase-in period allows continued screening, supporting the collection of clinical outcome data. Studies indicate that earlier diagnosis of PAD can lead to significant cost savings and improved patient outcomes. Semler aims to maintain rigorous testing protocols to benefit healthcare providers and patients.

Semler Scientific (Nasdaq: SMLR) reported a Q4 2022 revenue of $13.8 million, reflecting a 20% increase year-over-year, with net income rising 113% to $3.2 million. For full year 2022, revenues reached $56.7 million, a 7% increase, while net income decreased by 17% to $14.3 million. Cash position improved to $43.1 million. A transition in leadership was announced, as CEO Doug Murphy-Chutorian will step down, succeeded by Wayne T. Pan effective April 3, 2023. The company expects Q1 2023 revenue between $17.4 million and $17.8 million but has withheld guidance for the entire year.

Semler Scientific, Inc. (NASDAQ: SMLR) announced on March 21, 2023, that Doug Murphy-Chutorian, M.D. will step down as CEO but remain on the board through 2024. Wayne T. Pan, M.D., Ph.D., M.B.A., currently a board member since May 2014, will take over as CEO effective April 3, 2023. Dr. Pan brings over 20 years of wide-ranging healthcare experience, including his role as a medical director at Banner Health. In his statement, Dr. Pan expressed confidence in Semler's diagnostic tools, emphasizing their potential to improve cardiovascular care and enhance shareholder value.

S Santa Clara, Calif., March 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ: SMLR) announced it will report its financial results for Q4 and full-year 2022 on March 21, 2023, after U.S. markets close. CEO Doug Murphy-Chutorian will lead a conference call at 4:30 PM ET, alongside key executives from finance, marketing, and communications. Participants can pre-register for the call or dial in directly. Semler's mission focuses on improving clinical effectiveness through innovative healthcare solutions, including the FDA-cleared QuantaFlo® test for cardiovascular diseases.

Semler Scientific (SMLR) announced a study published in the Journal of Preventive Medicine validating QuantaFlo's role in diagnosing heart dysfunction. The study revealed a significant correlation (p<0.01) between QuantaFlo measurements and cardiac echocardiography, the gold standard in heart failure diagnosis. QuantaFlo offers a quick, non-invasive screening method, potentially transforming heart dysfunction detection in primary care. With 6.2 million heart failure cases in the U.S. and associated costs exceeding $30 billion, the early detection capability may lead to improved patient outcomes. Semler aims to enhance healthcare effectiveness with innovative solutions.

On December 14, 2022, Semler Scientific (SMLR) announced a study published in AJPM Focus, demonstrating the effectiveness of its QuantaFlo® PAD test in screening for peripheral artery disease (PAD) in-home. The study, analyzing data from 192,500 Medicare Advantage beneficiaries, revealed that 27.7% tested positive for PAD. Positive results correlated with significantly higher risk of mortality and cardiovascular events. The findings support the feasibility of a nationwide PAD screening program for older adults and may promote further adoption of QuantaFlo® by healthcare providers.

Semler Scientific (Nasdaq: SMLR) announced a $5.0 million investment in Monarch Medical Technologies via a senior secured convertible note, secured by Monarch's assets. Monarch's EndoTool® Glucose Management System is FDA cleared and used in over 100 U.S. health systems, optimizing inpatient glycemic management. This investment enhances Semler's diabetes management offerings alongside its Insulin Insights™ application. CEO Doug Murphy-Chutorian expressed confidence in Monarch's potential to assist healthcare providers amidst nursing shortages and CMS quality measures.

Semler Scientific (SMLR) reported its Q3 2022 financial results, revealing revenue of $14.0 million, unchanged from Q3 2021. Net income decreased to $3.7 million, or $0.55 per basic share, down from $4.2 million, or $0.61 per basic share a year prior. Cash and equivalents reached $45.5 million, up from $35.9 million in the prior year. Fixed fee software revenues rose 10% to $8.6 million, while variable fee revenues fell 16% to $4.9 million. For 2022, the revenue guidance was adjusted to $55.5 million to $58.0 million.

Semler Scientific, Inc. (Nasdaq: SMLR) has announced it will release its financial results for the third quarter and first nine months of 2022 on November 1, 2022, after U.S. market close. The CEO, Doug Murphy-Chutorian, will lead a conference call at 4:30 pm ET that day, featuring senior executives from the company. Semler Scientific specializes in technology solutions for healthcare, including the FDA-cleared QuantaFlo® test for cardiovascular diseases. They also market Insulin Insights™ and are developing new products to enhance patient care.